Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
stimulant medication
|
| gptkbp:activeDuring |
methylphenidate
|
| gptkbp:brand |
gptkb:Quillivant_XR
gptkb:Concerta gptkb:Ritalin_LA Daytrana Metadate Aptensio XR Focalin QuilliChew ER |
| gptkbp:chemicalFormula |
C14H19NO2
|
| gptkbp:clinicalTrials |
gptkb:National_Institute_for_Health_and_Care_Excellence
gptkb:American_Psychiatric_Association gptkb:American_Academy_of_Pediatrics |
| gptkbp:contraindication |
cardiovascular issues
irritability glaucoma mood swings heart problems tics psychosis hyperthyroidism |
| gptkbp:dosageForm |
oral tablet
oral suspension transdermal patch |
| gptkbp:drugInterdiction |
requires prescription
central nervous system stimulant |
| gptkbp:duration |
3 to 6 hours
|
| gptkbp:formFactor |
tablet
solution extended-release tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Ritalin
|
| gptkbp:inheritsFrom |
20 to 60 minutes
|
| gptkbp:interactsWith |
gptkb:MAO_inhibitors
antidepressants antihypertensives warfarin anticonvulsants |
| gptkbp:legalStatus |
controlled substance
|
| gptkbp:manufacturer |
Novartis
|
| gptkbp:numberOfStudents |
2 to 4 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:releaseYear |
1944
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
anxiety
headache nausea decreased appetite insomnia |
| gptkbp:usedFor |
treatment of ADHD
treatment of narcolepsy |